Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG0895.HCl in Advanced Solid Tumors
NCT05877664Phase 1Recruiting
- Sponsor
- Zelgen
- Start
- Aug 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ZG0895 in solid tumor, sponsored by Zelgen. Primary endpoints: Incidence of Dose-Limiting Toxicity at Day 21, Maximum Tolerated Dose at Day 21 and 2 more. Started Aug 2023; status: recruiting.
02
Drugs
ZG0895
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05877664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05877664.